REVIEW PAPER
Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management
Submission date: 2018-05-11
Final revision date: 2018-07-16
Acceptance date: 2018-07-18
Online publication date: 2018-08-31
Publication date: 2018-08-31
Reumatologia 2018;56(4):249-254
KEYWORDS
TOPICS
ABSTRACT
Interstitial lung disease (ILD) is a group of lung diseases characterized by thickening of the interstitium surrounding pulmonary alveolar walls. It is related to specific radiographic features in lung imaging and/or the presence of restrictive disorders in pulmonary function tests (PFTs). ILD is one of the leading causes of death in systemic sclerosis patients. Major risk factors of ILD associated with SSc (SSc-ILD) include male sex, diffuse type of cutaneous SSc and presence of anti-Scl-70 antibodies.
SSc-ILD is challenging to diagnose at an early stage as the symptoms are non-specific. The greatest risk of its development is during the 4–5 years after the initial diagnosis of systemic sclerosis. Clinical vigilance at the time, including regular pulmonary function tests and/or high-resolution com-puted tomography (HRCT), is needed. The aim of this paper is to summarize the current knowledge on early diagnostic methods and progression risk factors for SSc-ILD.
SSc-ILD is challenging to diagnose at an early stage as the symptoms are non-specific. The greatest risk of its development is during the 4–5 years after the initial diagnosis of systemic sclerosis. Clinical vigilance at the time, including regular pulmonary function tests and/or high-resolution com-puted tomography (HRCT), is needed. The aim of this paper is to summarize the current knowledge on early diagnostic methods and progression risk factors for SSc-ILD.
REFERENCES (44)
1.
Giacomelli R, Liakouli V, Berardicurti O, et al. Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatol Int 2017; 37: 1-11.
2.
Silver KC, Silver RM. Management of systemic-sclerosis-associated interstitial lung disease. Rheum Dis Clin North Am 2015; 41: 439-457.
3.
Strickland G, Pauling J, Cavill C, et al. Mortality in systemic sclerosis-a single centre study from the UK. Clin Rheumatol 2013; 32: 1533-1539.
4.
Schoenfeld SR, Castelino FV. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2015; 41: 237-248.
5.
Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003; 62: 97-99.
6.
Bauer PR, Schiavo DN, Osborn TG, et al. Influence of interstitial lung disease on outcome in systemic sclerosis: A population-based historical cohort study. Chest 2013; 144: 571-577.
7.
Solomon JJ, Olson AL, Fischer A, et al. Scleroderma lung disease. Eur Respir Rev 2013; 22: 6-19.
8.
Khanna D, Nagaraja V, Tseng C, et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials. Arthritis Res Ther 2015; 17: 372.
9.
Park SO, Seo JB, Kim N, et al. Comparison of usual interstitial pneumonia and nonspecific interstitial pneumonia: Quantification of disease severity and discrimination between two diseases on HRCT using a texture-based automated system. Korean J Radiol 2011; 12: 297-307.
10.
Bastos AL, Corręa RA, Ferreira GA. Tomography patterns of lung disease in systemic sclerosis. Radiol Bras 2016; 49: 316-321.
11.
Okamoto M, Fujimoto K, Sadohara J, et al. A retrospective cohort study of outcome in systemic sclerosis-associated interstitial lung disease. Respir Investig 2016; 54: 445-453.
12.
Cappelli S, Guiducci S, Bellando Randone S, et al. Immunosuppression for interstitial lung disease in systemic sclerosis. Eur Respir Rev 2013; 22: 236-243.
13.
Frauenfelder T, Winklehner A, Nguyen TD, et al. Screening for interstitial lung disease in systemic sclerosis: performance of high-resolution CT with limited number of slices: a prospective study. Ann Rheum Dis 2014; 73: 2069-2073.
14.
Branley HM. Pulmonary fibrosis in systemic sclerosis: Diagnosis and management. Respir Med CME 2010; 3: 10-14.
15.
Goldin JG, Lynch DA, Strollo DC, et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 2008; 134: 358-367.
16.
Grzanka P, Bestry I. Choroby układu oddechowego. Badania diagnostyczne. Badania obrazowe. In: Choroby wewnętrzne, Szczeklik A (ed.). Medycyna Praktyczna, Kraków 2011: 553-560.
17.
Farrokh D, Abbasi B, Fallah-Rastega Y, et al. The extrapulmonary manifestations of systemic sclerosis on chest high resolution computed tomography. Tanaffos 2015; 14: 193-200.
18.
Evison M, Crosbie PA, Morris J, et al. A study of patients with isolated mediastinal and hilar lymphadenopathy undergoing EBUS-TBNA. BMJ Open Respir Res 2014; 1: 11-13.
19.
Degano B, Soumagne T, Eberst G, et al. Pulmonary function parameters other than vital capacity should be considered in screening for interstitial lung disease in patients with systemic sclerosis: Comment on the article by Suliman et al. Arthritis Rheumatol 2016; 68: 2346-2347.
20.
Gigante A, Rossi Fanelli F, Lucci S, et al. Lung ultrasound in systemic sclerosis: correlation with high-resolution computed tomography, pulmonary function tests and clinical variables of disease. Intern Emerg Med 2016; 11: 213-217.
21.
Buda N, Piskunowicz M, Porzezińska M, et al. Lung ultrasonography in the evaluation of interstitial lung disease in systemic connective tissue diseases: criteria and severity of pulmonary fibrosis – analysis of 52 patients. Ultraschall Med 2016; 37: 379-385.
22.
Sperandeo M, De Cata A, Molinaro F, et al. Ultrasound signs of pulmonary fibrosis in systemic sclerosis as timely indicators for chest computed tomography. Sand J Rheumatol 2015; 44: 389-398.
23.
Pinal-Fernandez I, Pallisa-Nuńez E, Selva-O’Callaghan A, et al. Pleural irregularity, a new ultrasound sign for the study of interstitial lung disease in systemic sclerosis and antisynthetase syndrome. Clin Exp Rheumatol 2015; 33 (Suppl 91): 136-141.
24.
Gargani L, Doveri M, D’Errico L, et al. Ultrasound lung comets in systemic sclerosis: a chest sonography hallmark of pulmonary interstitial fibrosis. Rheumatology 2009; 48: 1382-1387.
25.
Delle Sedie A, Carli L, Cioffi E, et al. The promising role of lung ultrasound in systemic sclerosis. Clin Rheumatol 2012; 31: 1537-1541.
26.
Wang Y, Gargani L, Barskova T, et al. Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease: a literature review. Arthritis Res Ther 2017; 19: 206.
27.
Suliman YA, Dobrota R, Huscher D, et al. Pulmonary function tests: High rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol 2015; 67: 3256-3261.
28.
Cappelli S, Bellando Randone S, Camiciottoli G, et al. Interstitial lung disease in systemic sclerosis: Where do we stand? Eur Respir Rev 2015; 24: 411-419.
29.
Bernstein EJ, Khanna D, Lederer DJ. Screening high resolution computed tomography of the chest to detect interstitial lung disease in systemic sclerosis: A global survey of rheumatologists. Arthritis Rheumatol 2018; 70: 971-972.
30.
Adler S, Huscher D, Siegert E, et al. Systemic sclerosis associated interstitial lung disease – individualized immunosuppressive therapy and course of lung function: Results of the EUSTAR group. Arthritis Res Ther 2018; 20: 1-12.
31.
Herzog EL, Mathur A, Tager AM, et al. Interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: How similar and distinct? Arthritis Rheumatol 2014; 66: 1967-1978.
32.
Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 2013; 52: 155-160.
33.
Kwon HM, Kang EH, Park JK, et al. A decision model for the watch-and-wait strategy in systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford) 2015; 54: 1792-1796.
34.
Liu X, Mayes MD, Pedroza C, et al. Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res 2013; 65: 1-11.
35.
Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: A systematic review. Chest 2014; 146: 422-436.
36.
Sánchez-Cano D, Ortego-Centeno N, Callejas JL, et al. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. Rheumatol Int 2018; 38: 363-374.
37.
Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-1254.
38.
Yasuoka H. Recent treatments of interstitial lung disease with systemic sclerosis. Clin Med Insights Circ Respir Pulm Med 2015; 9: 97-110.
39.
Moore OA, Proudman SM, Goh N, et al. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. Clin Exp Rheumatol 2015; 33: 111-116.
40.
Lota HK, Renzoni EA. Circulating biomarkers of interstitial lung disease in systemic sclerosis. Int J Rheumatol 2012; 2012: 121439.
41.
Bonella F, Caramaschi P. The ambitious goal of validating prognostic biomarkers for systemic sclerosis-related interstitial lung disease. J Rheumatol 2013; 40: 1034-1036.
42.
Ligon C, Hummers LK. Biomarkers in Scleroderma: Progressing from Association to Clinical Utility. Curr Rheumatol Rep 2016; 18: 17.
43.
Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283-1289.
44.
Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017; 76: 1327-1339.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
